CN104490893B - 一种治疗失眠的药物组合物 - Google Patents
一种治疗失眠的药物组合物 Download PDFInfo
- Publication number
- CN104490893B CN104490893B CN201410722860.6A CN201410722860A CN104490893B CN 104490893 B CN104490893 B CN 104490893B CN 201410722860 A CN201410722860 A CN 201410722860A CN 104490893 B CN104490893 B CN 104490893B
- Authority
- CN
- China
- Prior art keywords
- insomnia
- cure
- pharmaceutical composition
- compound
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 14
- 206010022437 insomnia Diseases 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- -1 antiseptic Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
Abstract
本发明涉及一种治疗失眠的药物组合物，所述药物组合物包含有效量的化合物和药学上可接受的载体，所述化合物具有下列结构：
Description
技术领域
本发明涉及医药领域，具体的说，本发明涉及一种治疗失眠的药物组合物。
背景技术
失眠是指睡眠不足或睡不熟的一种睡眠障碍。可分为入睡困难，时常觉醒、早醒等。主要原因有精神过度紧张或兴奋疼痛、环境嘈杂、服用兴奋性饮料或药物以及躯体性疾病等。一般多伴有疲劳、不安、全身不适、无精打采、反应迟缓、头痛、记忆力不集中等症状。它的最大影响是精神方面的，严重一点会导致精神分裂。常影响人们正常的生活、学习、工作和健康。若长期不寐，将给病人带来巨大的痛苦。
发明内容
本发明的目的在于提供一种治疗失眠的药物组合物。
为了实现本发明的目的，本发明提供一种治疗失眠的化合物，该化合物具有下列结构：
本发明还提供一种治疗失眠的药物组合物，所述药物组合物包含有效量的化合物和药学上可接受的载体，所述化合物具有下列结构：
优选地，所述药学上可接受的载体为稀释剂、崩解剂、粘合剂、润滑剂、稳定剂或矫正剂。
优选地，所述稀释剂为糖衍生物、淀粉衍生物或纤维素衍生物。
优选地，所述稀释剂为乳糖。
优选地，所述药物组合物为散剂、微粒剂、颗粒剂、胶囊剂或片剂。
本发明还提供化合物在制备治疗失眠的药物中的用途，该化合物具有下列结构：
本文所用的术语“药学上可接受的”指不消除本文所述的化合物的生物学活性或性质的物质，如载体或稀释剂。这类物质被施用于个体不导致不希望的生物学作用或者不以有害方式与包含它的组合物中的任何组分相互作用。
如本文所用的术语“药学上可接受的载体”包括任何和所有的溶剂、分散介质、包衣材料、表面活性剂、抗氧化剂、防腐剂(例如抗菌剂、抗真菌剂)、等渗剂、吸收延迟剂、盐、防腐剂、药物稳定剂、粘合剂、赋形剂、崩解剂、润滑剂、甜味剂、矫味剂、染料等和其组合，这是本领域技术人员所熟知的(例如参见Remington'sPharmaceuticalSciences,18thEd.MackPrintingCompany,1990,pp.1289-1329)。除了与活性成分不相容的载体外，在治疗或药物组合物中考虑使用任何常规载体。
经动物实验证明，本发明的化合物能够安全有效治疗失眠
具体实施方式
以下通过具体实施方式的描述对本发明作进一步说明，但这并非是对本发明的限制，本领域技术人员根据本发明的基本思想，可以做出各种修改或改进，但是只要不脱离本发明的基本思想，均在本发明的范围之内。
实验例本发明化合物对小鼠睡眠时间的影响
取NIH小鼠50只，20±2g，随机分为五组，分别为生理盐水组，安定阳性对照组、化合物高剂量组、化合物中剂量组和化合物低剂量组，每组10只。灌胃给药，40分钟后，腹腔注射戊巴比妥钠40mg/kg，记录小鼠的睡眠时间，即翻正反射消失时间。结果见下表1。数据使用SPSS13.0进行统计。
表1
*和生理盐水组相比，P<0.05；和阳性对照组相比，P>0.05
由上表可见，本发明化合物和生理盐水组相比，具有显著性差别。本发明化合物的高剂量组和阳性安定对照组的效果相比，没有显著性差别。这说明，本发明化合物的镇静催眠效果极佳，非常适合开发出成功的临床药物。
Claims (1)
1.化合物在制备治疗失眠的药物中的用途，其特征在于，该化合物具有下列结构：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410722860.6A CN104490893B (zh) | 2014-12-02 | 2014-12-02 | 一种治疗失眠的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410722860.6A CN104490893B (zh) | 2014-12-02 | 2014-12-02 | 一种治疗失眠的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104490893A CN104490893A (zh) | 2015-04-08 |
| CN104490893B true CN104490893B (zh) | 2016-01-06 |
Family
ID=52932408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410722860.6A Active CN104490893B (zh) | 2014-12-02 | 2014-12-02 | 一种治疗失眠的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490893B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218465A (zh) * | 2015-11-14 | 2016-01-06 | 刘杰 | 一种治疗乳腺癌的药物组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546037A (zh) * | 2003-12-08 | 2004-11-17 | 南昌弘益科技有限公司 | 地西泮滴丸及其制备方法 |
| US20080279784A1 (en) * | 2007-05-07 | 2008-11-13 | Questcor Pharmaceuticals, Inc. | Nasal administration of benzodiazepines |
-
2014
- 2014-12-02 CN CN201410722860.6A patent/CN104490893B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546037A (zh) * | 2003-12-08 | 2004-11-17 | 南昌弘益科技有限公司 | 地西泮滴丸及其制备方法 |
| US20080279784A1 (en) * | 2007-05-07 | 2008-11-13 | Questcor Pharmaceuticals, Inc. | Nasal administration of benzodiazepines |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104490893A (zh) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| JP2019512495A5 (zh) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| CN104490893B (zh) | 一种治疗失眠的药物组合物 | |
| JP2020536854A5 (zh) | ||
| US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
| CN101467967A (zh) | 用于静脉和脑内注射的两元溶液型制剂 | |
| CN101757016A (zh) | 一种治疗感冒的药物组合物及制备方法 | |
| CN106038522A (zh) | 大黄酸在制备抗抑郁症药物中的用途 | |
| CN110559287A (zh) | 一种用于治疗癌症的药物组合物及其应用 | |
| CN104274009B (zh) | 一种具有治疗失眠多梦功能的中药靠枕 | |
| CN105801510A (zh) | 一种治疗抑郁症的药物组合物 | |
| Nuri et al. | Papaya leaves juice as an alternative treatment for dengue fever | |
| CN104622881A (zh) | 一种药物组合物及其在制备治疗抑郁症的药物中的应用 | |
| CN101559037A (zh) | 用于静脉和脑内注射的两元溶液型制剂 | |
| CN113827603B (zh) | 瑞德西韦在制备治疗胶质瘤药物中的应用 | |
| CN108853111B (zh) | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 | |
| CN106511341B (zh) | 一种治疗慢性支气管炎的药物 | |
| CN103933034B (zh) | 一种含有木犀草素的药物组合物及应用 | |
| CN104107206B (zh) | 杭菊提取物在制备防治高血糖保健食品和药品中的应用 | |
| EP3127427A1 (en) | Methods of administration of thrombopoietin agonist compounds | |
| CN107088191A (zh) | 药物泰尔登的新用途 | |
| KR20230019300A (ko) | 부형제를 사용하지 않는 정제 및 캡슐의 제조방법 및 상기 제조방법으로 제조된 수면영양제 | |
| CN110075302A (zh) | 一种治疗抑郁和失眠的组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Yan Inventor before: Li Zhigang |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151204 Address after: 226600 Haian, Nantong, Haian economic and Technological Development Zone, West Beihai Road, No. 4, No. Applicant after: LI FUJUN Address before: 050051 No. 118, cooperation Road, Shijiazhuang, Hebei Applicant before: Li Zhigang |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200420 Address after: Room 1018, building 2, No. 85, Sandun Road, Xiangfu street, Gongshu District, Hangzhou City, Zhejiang Province Patentee after: HANGZHOU MEIYA PHARMACY Co.,Ltd. Address before: 226600, No. 4 West Beihai Road, Haian economic and Technological Development Zone, Haian County, Jiangsu, Nantong Patentee before: MEIYA PHARMACEUTICAL HAIAN Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200702 Address after: 226600 No.40, Kanghua Road, Chengdong Town, Hai'an County, Nantong City, Jiangsu Province Patentee after: MEIYA PHARMACEUTICAL HAIAN Co.,Ltd. Address before: Room 1018, building 2, No. 85, Sandun Road, Xiangfu street, Gongshu District, Hangzhou City, Zhejiang Province Patentee before: HANGZHOU MEIYA PHARMACY Co.,Ltd. |